Analyst Conference Summaries

Biotechnology Investor Aids

Protalix BioTherapeutics
PLX

conference date: November 8, 2017 @ 5:30 AM Pacific Time

FDA Okays Phase 3 Study of PRX-102 for Fabry Disease [November 16, 2015]

Protalix Positive Preclinical Results for NASH [October 5, 2015]
Protalix Positive Interim Phase I/II Data for PRX-102 [Jan. 8, 2015]
Protalix: Undervalued Growth, Plus a Possible Biotech Breakthrough [Oct. 30, 2013 @ Seeking Alpha]

2017
 
May 10, 2017
August 9, 2017
Nov. 8, 2017
 
2016
05/09/2016
08/08/2016
11/09/2016
03/16/2017
2015
 05/07/2015
08/10/2015 
 11/09/2015
 03/08/2016

Protalix BioTherapeutics (PLX) is a biotechnology company making proprietary recombinant therapeutic proteins with its ProCellEx plant cell based protein expression system.

Protalix does not currently hold quarterly conference calls for analysts. It is based in Israel, but registered in Florida and files with the SEC.

Protalix BioTherapeutics web site
Protalix investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2013 William P. Meyers